Peptides DB
Research-centric peptide and protocol reference hub
Study 13 of 34Octreotide literaturebiorxiv-preprint · Review2026

Carcinoid Heart Disease: Surgical Timing, Right Ventricular Risk Stratification and Operative Strategy

Operative mortality for carcinoid heart disease is now 5–6% in high-volume centers, and continuous octreotide infusion can reduce carcinoid crisis incidence.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the octreotide corpus
1
Preclinical
28
Observational
0
Open-label
3
Randomised
2
Reviews · this one

Summary and findings

This review addresses carcinoid heart disease, focusing on surgical timing and right ventricular risk stratification. It reports that operative mortality has decreased to 5–6% in high-volume centers and emphasizes the importance of preoperative right ventricular function. Continuous perioperative octreotide infusion is noted to have reduced the incidence of carcinoid crisis.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
5–6% operative mortality in contemporary high-volume centres.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

Carcinoid heart disease is a progressive right-sided valvulopathy caused by serotonin and other vasoactive mediators released by metastatic neuroendocrine tumours. As oncological therapies have extended survival, cardiac disease has become a leading determinant of mortality. Operative mortality has decreased to 5–6% in contemporary high-volume centres, and long-term survival appears increasingly determined by tumour biology rather than cardiac disease when surgery is appropriately timed. The principal determinant of operative outcome is preoperative right ventricular function; symptom-based referral alone is insufficient because many patients remain compensated until ventricular dysfunction is advanced. This review synthesises the evidence on surgical timing, operative strategy, prosthesis selection, perioperative endocrine management, and emerging transcatheter options. Tricuspid valve replacement is required in the majority of patients, with concomitant pulmonary valve replacement advocated where concurrent disease is present. Bioprosthetic valves are preferred. Continuous perioperative octreotide infusion has substantially reduced the incidence of carcinoid crisis. Structured multidisciplinary decision-making integrating echocardiographic surveillance, biomarker monitoring, and oncological status assessment is essential.

Elsewhere in the Octreotide corpus

BCongenital hyperinsulinism as part of a multisystem disease caused by a compound heterozygous variant in the <i>YARS1</i> gene.JCEM case reports · 2023 · n=1 · Not reported in abstract.HumanBManagement of Chylous Acid in Gynecological Malignanciesbiorxiv-preprint · 2026 · On postoperative day 4, median drainage output in TPN-requiring patients was 830 mL.HumanCThe role of biorelevant media components on the diffusion and enzymatic stability of oral cyclic peptide analogs.International journal of pharmaceutics · 2026 · Not reported in abstract.In vitroCActivation of the dopamine D2 receptor enhances colonic motility via disinhibition of somatostatinergic signalling in rodents.European journal of pharmacology · 2026 · Not reported in abstract.AnimalBMetastatic proinsulin-secreting tumor: a rare cause of persistent hypoglycemia.JCEM case reports · 2023 · n=1 · Not reported in abstract.HumanCThe Extent of Ligand-Receptor Interactions for Actively Targeted Nanoparticles as a Function of Ligand Density and Receptor Expression.ACS applied materials & interfaces · 2026 · Not reported in abstract.In vitro